De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Intellia Therapeutics Beheer
Beheer criteriumcontroles 2/4
De CEO Intellia Therapeutics' is John Leonard, benoemd in Jan2018, heeft een ambtstermijn van 6.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 11.66M, bestaande uit 5.7% salaris en 94.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.82% van de aandelen van het bedrijf, ter waarde $ 17.07M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.1 jaar en 9.5 jaar.
Belangrijke informatie
John Leonard
Algemeen directeur
US$11.7m
Totale compensatie
| Percentage CEO-salaris | 5.7% |
| Dienstverband CEO | 6.8yrs |
| Eigendom CEO | 0.8% |
| Management gemiddelde ambtstermijn | 6.1yrs |
| Gemiddelde ambtstermijn bestuur | 9.5yrs |
Recente managementupdates
Recent updates
Intellia - Exciting Promise Of First In-Vivo Gene Therapy Makes Bull Case
Sep 25We're Keeping An Eye On Intellia Therapeutics' (NASDAQ:NTLA) Cash Burn Rate
Sep 07
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Aug 11Intellia Therapeutics Is Expanding The Scope Of Gene Editing (Technical Analysis)
Aug 03Here's Why It's Unlikely That Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) CEO Will See A Pay Rise This Year
Jun 06Intellia Therapeutics Presents Promising In Vivo CRISPR Results
Jun 05Industry Analysts Just Made A Dazzling Upgrade To Their Intellia Therapeutics, Inc. (NASDAQ:NTLA) Revenue Forecasts
May 14Intellia Therapeutics: 3 Near-Term Pivotal In Vivo Gene Therapies
May 13Intellia Therapeutics Is On The Move
Feb 29Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Feb 24Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier
Feb 09Is Intellia Therapeutics (NASDAQ:NTLA) In A Good Position To Deliver On Growth Plans?
Feb 07Is There An Opportunity With Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) 25% Undervaluation?
Jan 01Intellia Therapeutics (NASDAQ:NTLA) Is In A Good Position To Deliver On Growth Plans
Oct 20Intellia Therapeutics: Top Speculative Trade In The Biotech Space
Oct 05Intellia wins FDA orphan drug designation for genome editing therapy for severe swelling
Sep 01Is Intellia Therapeutics (NASDAQ:NTLA) Weighed On By Its Debt Load?
Aug 06Intellia Therapeutics down 12% following bottom line Q2 earnings miss
Aug 04Intellia: Slim Hopes Of Near-Term Commercial Revenue Makes Me Bearish
Jul 28Intellia Therapeutics: Several Catalysts Expected For H2 2022
May 12Intellia: One Patent Ruling Turns The Industry Upside Down
Mar 09Intellia Therapeutics: A Lot Of News Can Bring The Stock Up
Feb 25Need To Know: The Consensus Just Cut Its Intellia Therapeutics, Inc. (NASDAQ:NTLA) Estimates For 2022
Feb 09Intellia: Best All-Around Gene Editing Company
Jan 27We Think Intellia Therapeutics (NASDAQ:NTLA) Can Afford To Drive Business Growth
Dec 31Intellia Has Potential As Gene Therapy Play With Second Product Being Tested In Humans
Dec 15Intellia Stock: Setting Up For Success
Nov 29Intellia: A Step Closer To A Life-Changing Cure
Nov 21Intellia Therapeutics, Inc.'s (NASDAQ:NTLA) Intrinsic Value Is Potentially 79% Above Its Share Price
Oct 11Intellia's Data Has Underlined Huge Potential Of Gene Therapeutics And There Will Be More Soon
Aug 31Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$509m |
| Mar 31 2024 | n/a | n/a | -US$486m |
| Dec 31 2023 | US$12m | US$660k | -US$481m |
| Sep 30 2023 | n/a | n/a | -US$462m |
| Jun 30 2023 | n/a | n/a | -US$453m |
| Mar 31 2023 | n/a | n/a | -US$430m |
| Dec 31 2022 | US$10m | US$630k | -US$474m |
| Sep 30 2022 | n/a | n/a | -US$442m |
| Jun 30 2022 | n/a | n/a | -US$400m |
| Mar 31 2022 | n/a | n/a | -US$369m |
| Dec 31 2021 | US$10m | US$600k | -US$268m |
| Sep 30 2021 | n/a | n/a | -US$229m |
| Jun 30 2021 | n/a | n/a | -US$185m |
| Mar 31 2021 | n/a | n/a | -US$149m |
| Dec 31 2020 | US$4m | US$580k | -US$134m |
| Sep 30 2020 | n/a | n/a | -US$120m |
| Jun 30 2020 | n/a | n/a | -US$116m |
| Mar 31 2020 | n/a | n/a | -US$109m |
| Dec 31 2019 | US$904k | US$559k | -US$100m |
| Sep 30 2019 | n/a | n/a | -US$90m |
| Jun 30 2019 | n/a | n/a | -US$89m |
| Mar 31 2019 | n/a | n/a | -US$86m |
| Dec 31 2018 | US$10m | US$550k | -US$85m |
| Sep 30 2018 | n/a | n/a | -US$90m |
| Jun 30 2018 | n/a | n/a | -US$83m |
| Mar 31 2018 | n/a | n/a | -US$76m |
| Dec 31 2017 | US$3m | US$396k | -US$68m |
Compensatie versus markt: De totale vergoeding ($USD 11.66M ) John } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 5.54M ).
Compensatie versus inkomsten: De vergoeding van John is gestegen terwijl het bedrijf verliesgevend is.
CEO
John Leonard (67 yo)
6.8yrs
Tenure
US$11,657,262
Compensatie
Dr. John M. Leonard, M. D. is an Executive Partner at Tyree & D'Angelo Partners. He serves as Director at 3T Biosciences, Inc. since October 2022. He has been Independent Director at IQVIA Holdings Inc. si...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 6.8yrs | US$11.66m | 0.82% $ 14.9m | |
| Executive VP & Chief Scientific Officer | 5.4yrs | US$4.19m | 0.019% $ 348.3k | |
| Executive VP | 3.3yrs | US$3.99m | 0.017% $ 319.1k | |
| Executive VP & Chief Medical Officer | 4.5yrs | US$4.26m | 0.029% $ 527.4k | |
| Founder & Member of Scientific Advisor Board | 10.4yrs | US$11.27m | geen gegevens | |
| Co-Founder | 10.4yrs | US$311.57k | geen gegevens | |
| Founder and Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens |
6.1yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van NTLA is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.1 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| President | 10.3yrs | US$11.66m | 0.82% $ 14.9m | |
| Founder & Member of Scientific Advisor Board | no data | US$11.27m | geen gegevens | |
| Founder and Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | 9.5yrs | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | 9.5yrs | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Founder & Member of Scientific Advisor Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | no data | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 9.8yrs | geen gegevens | geen gegevens | |
| Independent Chairman of the Board | 7.3yrs | US$499.94k | 0.010% $ 183.7k | |
| Independent Director | 1.5yrs | US$996.21k | 0.0067% $ 122.3k |
9.5yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van NTLA wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.5 jaar).